Subsidies & Funding

We empower medical innovation

Project Management

We manage research & innovation projects

Business Strategy

We support successful commercialisation


Times of accelerating eHealth innovation – funding opportunities

October 14 2016

According to Google CEO Sundar Pichai we are in the transition from a mobile-first era to the artificial-intelligence (AI)-first era. Given the ever-accelerating rate of digital innovation, it is safe to assume that AI will be part of our daily lives sooner rather than later. The internet-of-things is already part of healthcare and well-being and care is following the general trend of digitalization. We are at the eve of many exciting developments in eHealth.


In broad terms eHealth entails technological themes that support either diagnostics or care- and lifestyle decision-making. Mobile health (mHealth) is a special form of eHealth, a term used for the practice of medicine and public health supported by mobile devices. In Western countries, >70% of the population has access to a tablet or smartphone, making mHealth easy, fast, and cheap entry-point for care. This also means that mHealth had the capacity to have real impact in third-world countries.

Trend toward mHealth

mHealth applications include the use of mobile devices in collecting community and clinical health data, delivery of healthcare information to practitioners, researchers, and patients, real-time monitoring of patients, and direct provision of care. This will facilitate better care and has the potential to decrease healthcare costs. Although only one-in-five healthcare professionals use mobile applications with their patients, 86% of the professionals believe mobile Apps will increase their knowledge of their patients' conditions, suggesting a huge market potential.

Funding for accelerating eHealth

Funding bodies recognize the unique opportunities that eHealth and mHealth bring and are keen on accelerating the use of beneficial applications. Between fast-tracking implementation of eHealth solution, personalized in silico trials to amend (or replace!) in vivo trials, and progressing the digitalization of patient information sharing, e-health and well-being are here to stay. The following topics are under consideration for inclusion in Calls for proposals:

Horizon 2020 – Societal challenge 1 health, demographic change, and wellbeing (€658M)


The challenge is to help overcome the current gaps in exploitation of promising research results in ICT for Health, Well-being and Ageing well and to stimulate increased availability and market uptake of relevant ICT products and services.

SC1-PM-17-2017: Personalised computer models and in-silico systems for wellbeing

More, innovative methods are needed for better understanding the influence of biological (including microbiome), social, environmental, lifestyle, occupational, economic etc. factors on human physiology and thereby on well-being and health. 

SC1-PM-16-2017: In-silico trials for developing and assessing biomedical products

A research and technological roadmap on in-silico trials that are the use of individualised computer simulations in testing is currently available showing both strong interest and potential benefit of expanding the computer-modelling in drugs and other biomedical products research.

SC1-PM-15-2017: Personalised coaching for well-being and care of people as they age

To provide personalised advice and guidance for age-related issues in daily life with solutions that are seamlessly integrated with existing every-day activities and provide desired information in a fast and efficient manner.

Dutch national initiative (> €20M)

The Netherlands “Fast track” program for eHealth scale-up.

At ttopstart we are specialized in the support of competitive grant applications in the area of life sciences and we have the expertise to position your eHealth or mHealth innovations for maximal impact. If you are developing eHealth or mHealth solutions and are seeking support for your project, feel free to contact ttopstart. 

Share this

Boaz van Driel, PhD
+31 614 842 950